title: [Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease].
abstract: OBJECTIVE
  Patients with Inflammatory Bowel Disease (IBD) may have an increased risk of developing hepatitis B virus (HB) infection. Invasive procedures such as colonoscopies and surgery might be some of the reasons for this. Moreover, the use of immunosuppressors may reactivate a latent infection. We assessed the immune status among IBD patients receiving HB vaccine and the circumstances that predicted its results.
  
  
  OBJECTIVE
  Serological markers of B and C hepatitis virus in patients with IBD who were referred for consultation were assessed since 2006. The subsequent determination of antibodies against superficial antigen (HBsAb) could differentiate between responders and non responders to the vaccine and an adequate immunity to HB was defined as higher than 10mUI/ml.
  
  
  RESULTS
  One hundred and twenty nine patients were included in our study. Fifty-six (43,4%) patients had received immunosuppressive medication before the first vaccine dose. Notably, 85 (65.9%) patients had inadequate levels of HBsAb: 36 had no detectable levels and 49 had less than 10mUI/ml. Younger patients had a better immunity response than older patients (30.91+/-14.8 vs 39.91+/-14.2) (p<0.001).
  
  
  CONCLUSIONS
  More than half of the patients had a suboptimal serologic response after vaccination. Only the younger group showed a better rate of response. It was not demonstrated whether an additional fourth dose of vaccination or a complete revaccination improved the rate of responders.
authors.affiliation: Unidad de Gestión Clínica de Aparato Digestivo, Area Médica, Hospital Universitario Reina Sofía, Córdoba, España. lvp80@hotmail.com
authors.forename: Luis
authors.initials: L
authors.lastname: Vida Pérez
authors.forename: Federico
authors.initials: F
authors.lastname: Gómez Camacho
authors.forename: Valle
authors.initials: V
authors.lastname: García Sánchez
authors.forename: Eva M A
authors.initials: EM
authors.lastname: Iglesias Flores
authors.forename: Laura
authors.initials: L
authors.lastname: Castillo Molina
authors.forename: Antonio
authors.initials: A
authors.lastname: Cerezo Ruiz
authors.forename: Luis
authors.initials: L
authors.lastname: Casáis Juanena
authors.forename: Juan Francisco
authors.initials: JF
authors.lastname: De Dios Vega
mesh_terms: D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000150:complications / Q000276:immunology*; D008297:Male
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines